A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

Leukemia

Volumn 25, Issue 12, 2011, Pages 1808-1814

  Lancet, J E ^a   Ravandi, F ^b   Ricklis, R M ^c   Cripe, L D ^d   Kantarjian, H M ^b   Giles, F J ^e   List, A F ^a   Chen, T ^f   Allen, R S ^f   Fox, J A ^f   Michelson, G C ^f   Karp, J E ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f Sunesis Pharmaceuticals Inc   (United States)

Author keywords

acute leukemia; phase 1; quinolone derivative; relapsed refractory; voreloxin; vosaroxin

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE H2AX; QUINOLONE DERIVATIVE; VOSAROXIN;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; COUGHING; CYTOGENETICS; DIARRHEA; DNA DAMAGE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; INFECTION; INTESTINE OBSTRUCTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MORTALITY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; PERIPHERAL EDEMA; PETECHIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; REFRACTORY LEUKEMIA; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 83555165090     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.157     Document Type: Article

References (29)

1. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154-1163. (Pubitemid 41130866)
2. Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ et al. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Brit J Haematol 2010; 148: 217-225.
3. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood 1997; 89: 3323-3329.
4. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood 1999; 94: 1086-1099. (Pubitemid 29361842)
5. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108: 2358-2365. (Pubitemid 44497520)
6. Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003; 17: 995-997. (Pubitemid 36626336)
7. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009; 113: 6215-6224.
8. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003; 9: 1158-1165. (Pubitemid 37173700)
9. Fathi AT, Karp JE. New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines. Curr Oncol Rep 2009; 11: 346-352.
10. Giles F, Vey N, DeAngelo D, Seiter K, Stock W, Stuart R et al. Phase III randomized, placebo-controlled, double-blind study of high dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood 2009; 114: 4027-4033.
11. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009; 59: 111-137.
12. Shah BD, Lancet JE. Frontline treatment of acute myeloid leukemia: are we making progress? In: Govindan R (ed). American Society of Clinical Oncology Education Book. American Society of Clinical Oncology: Alexandria, VA, 2009, pp 372-377.
13. Hawtin RE, Stockett DE, Byl JA, McDowell RS, Nguyen T, Arkin MR et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS ONE 2010; 5: e10186.
14. Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y et al. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol 2009; 64: 53-65.
15. Scatena CE, Kumer JL, Arbitrario JP, Howlett AR, Hawtin RE, Fox JA et al. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol 2010; 66: 881-888.
16. van der Kolk DM, de Vries EG, Mü ller M, Vellenga E. The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 2002; 43: 685-701. (Pubitemid 34428655)
17. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, 8/06. http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3.pdf.
18. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649. (Pubitemid 46594039)
19. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA doublestrand breaks. Cancer Res 2003; 63: 4347-4350. (Pubitemid 36951002)
20. Olive PL, Banath JP. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys 2004; 58: 331-335. (Pubitemid 38142456)
21. Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007; 110: 1762-1769. (Pubitemid 47443886)
22. Slovak ML, Kopecky KH, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075-4083.
23. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-5868. (Pubitemid 28124064)
24. Advani RH, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA et al. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res 2010; 16: 2167-2175.
25. Kell J. Treatment of relapsed acute myeloid leukemia. Rev Recent Clin Trials 2006; 1: 103-111.
26. Evanchik MJ, Allen D, Yoburn JC, Silverman JA, Hoch U. Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl) -4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metab Dispos 2009; 37: 594-601.
27. Speth PA, Linssen PC, Boezeman JB, Wessels HM, Haanen C. Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion. Cancer Chemother Pharmacol 1987; 20: 311-315. (Pubitemid 18007428)
28. Speth PA, Minderman H, Haanen C. Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies. Semin Oncol 1989; 16(Suppl 2): 2-9. (Pubitemid 19111366)
29. Galettis P, Boutagy J, Ma DD. Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia. Br J Cancer 1994; 70: 324-329. (Pubitemid 24247158)